Heart Failure

The purpose of this study is to investigate the safety and efficacy of empagliflozin versus placebo in patients with chronic heart failure with preserved ejection fraction.

Inclusion Criteria:

  • Male or female patient age >= 18 years at screening.
  • Patients with chronic HF (LVEF (Left Ventricular Ejection Fraction) >40%)
  • Further inclusion criteria apply

Exclusion Criteria:

  • Myocardial infarction, coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days prior to Visit 1.
  • History of ketoacidosis
  • Currently enrolled in another investigational device or drug study
  • Further exclusion criteria apply